Maximum quantity allowed is 999
请选择数量
CAS RN: 144598-75-4 | 產品號碼: P1897
| 產品號碼 | P1897 |
| 純度/分析方法 | >97.0%(T) |
| 分子式 / 分子量 | C__2__3H__2__7FN__4O__3 = 426.49 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器 | 1G-Glass Bottle with Plastic Insert （閲覽圖片）, 200MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 144598-75-4 |
| Reaxys-RN | 8808385 |
| PubChem Substance ID | 125307525 |
| SDBS (AIST Spectral DB) | 52833 |
產品規格
| Appearance | Light orange to Yellow to Green powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Purity(Nonaqueous Titration) | min. 97.0 % |
| NMR | confirm to structure |
性質
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H301 : Toxic if swallowed. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | UV1164720 |
運輸資料
| UN編號 | UN2811 |
| 類別 | 6.1 |
| 包裝類別 | III |
| HS編碼* | 2934.99-000 |
Application
Paliperidone (9-Hydroxyrisperidone): A dopamine D2 and Serotonin 5-HT2 Receptors Antagonist
Paliperidone (another name: 9-hydroxyrisperidone), a benzisoxazole derivative, is acts as a dopamine type 2 (D2) and serotonin type 2 (5-HT2) receptors antagonist, and the major active metabolite of risperidone [R0087]. Similarly to risperidone, paliperidone has also affinity for α1- and α2-adrenergic, and H1 histaminergic receptors. Paliperidone has no affinity for cholinergic muscarinic or β1- and β2-adrenergic receptors. The pharmacological activity of the (+)- and (-)-paliperidone enantiomers is qualitatively and quantitatively similar in vitro. Risperidone is used as an antipsychotic agent with relatively few side effects. Recently, paliperidone extended-release formulation is developed for clinical use. (The product is for research purpose only.)
References
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding
- The pipeline and future of drug development in schizophrenia (a review)
- Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia
- The pharmacokinetics of paliperidone versus risperidone (a review)
- Paliperidone extended release: a review of its use in the management of schizophrenia
考研文獻
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。